Search

Search Constraints

You searched for: Author/Creator Bygrave, Ceri

Search Results

1. COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trial. (21st November 2020)

2. Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma. (10th June 2020)

3. Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset. Issue 6 (26th June 2022)

4. Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK‐wide real‐world cohort of relapsed myeloma patients. (31st January 2023)

5. Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study. Issue 1 (31st December 2022)

6. Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience. Issue 6 (12th May 2021)

7. Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy. (10th June 2020)

8. Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. Issue 11 (17th November 2022)

9. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. (1st March 2021)